<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="621">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04458298</url>
  </required_header>
  <id_info>
    <org_study_id>OP-101-004</org_study_id>
    <nct_id>NCT04458298</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients</brief_title>
  <acronym>PRANA</acronym>
  <official_title>A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of OP-101 (Dendrimer N-acetyl-cysteine) in Patients With Severe COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orpheris, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orpheris, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose is to evaluate the safety and tolerability of OP-101 and secondary
      purpose is to determine the effect of OP-101 reducing proinflammatory cytokines after a
      single dose in severe COVID-19 Patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">November 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Treatment Emergent Adverse Events Graded as Assessed by CTCAE Version 4.0</measure>
    <time_frame>Up to Day 60</time_frame>
    <description>Number of participants with treatment emergent adverse events will be evaluated as a measure of safety and tolerability of OP-101 by monitoring and documenting all adverse events, which include laboratory test variables.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement (2 points) in Clinical Status Assessment Using the World Health Organization 7-Point Ordinal Scale (WHO 7OS)</measure>
    <time_frame>Up to Day 30</time_frame>
    <description>WHO-7 is a 7 point ordinal scale for clinical improvement with scores ranging from 0 to 7 where 0= uninfected, 1= no limitation of activities (ambulatory), 2= limitation of activities (ambulatory), 3= hospitalized, no oxygen therapy (hospitalized mild disease), 4= Hospitalized, oxygen by mask or nasal prongs (hospitalized mild disease), 5= Hospitalized, noninvasive ventilation or high-flow oxygen (hospitalized severe disease), 6= Hospitalized, intubation and mechanical ventilation (hospitalized severe disease), 7= Hospitalized, ventilation + additional organ support - pressors, renal replacement therapy, ECMO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Fever for at least 48 hours Without Antipyretics for Patients with Documented Fever (&gt;=37.2 degree celsius [oral], or &gt;=37.8 degree celsius [rectal], or &gt;=38.0 degree celsius [tympanic])</measure>
    <time_frame>Up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement in Oxygenation for at least 48 hours</measure>
    <time_frame>Up to Day 30</time_frame>
    <description>Improvement in oxygenation is defined by increase in pulse oxygen saturation/fraction of inspired oxygen (SpO2/FiO2) of &gt;=50 compared with nadir SpO2/FiO2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the World Health Organization (WHO)-7 Point Ordinal Scale</measure>
    <time_frame>Baseline up to Day 30</time_frame>
    <description>WHO-7 is a 7 point ordinal scale for clinical improvement with scores ranging from 0 to 7 where 0= uninfected, 1= no limitation of activities (ambulatory), 2= limitation of activities (ambulatory), 3= hospitalized, no oxygen therapy (hospitalized mild disease), 4= Hospitalized, oxygen by mask or nasal prongs (hospitalized mild disease), 5= Hospitalized, noninvasive ventilation or high-flow oxygen (hospitalized severe disease), 6= Hospitalized, intubation and mechanical ventilation (hospitalized severe disease), 7= Hospitalized, ventilation + additional organ support - pressors, renal replacement therapy, ECMO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discharge from Clinic or Hospital or to National Early Warning Score 2 (NEWS2) of &lt;=2 and maintained for 24 hours</measure>
    <time_frame>Up to Day 30</time_frame>
    <description>NEWS2 consists of: Physiological Parameters: Respiration rate (per minute), SpO2 Scale 1 (%), SpO2 Scale 2 (%), Use of Air or oxygen, Systolic blood pressure (mmHg), Pulse (per minute), Consciousness, Temperature (Â°C).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Alive and not Using Supplemental Oxygen at Time of Discharge from Hospital/Clinic or Day 30</measure>
    <time_frame>Up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Resting Respiratory Rate of more than 24 breath/min</measure>
    <time_frame>Up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days with Hypoxemia</measure>
    <time_frame>Up to Day 30</time_frame>
    <description>Hypoxemia is defined by Saturation of Peripheral Oxygen (SpO2) of less than (&lt;) 95 percent (%) on room air or acute respiratory distress syndrome (ARDS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Supplemental Oxygen use</measure>
    <time_frame>Up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Ventilator-free Days</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days in Intensive Care Unit (ICU)</measure>
    <time_frame>Up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Hospitalization for Survivors</measure>
    <time_frame>Up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with all cause deaths</measure>
    <time_frame>Up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Proinflammatory Cytokines</measure>
    <time_frame>Baseline up to Day 30</time_frame>
    <description>Percent change from baseline in proinflammatory cytokines (C-reactive protein [CRP], ferritin, and interleukin-6 [IL-6]) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Drug-related Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Day 60</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Cohort A: OP-101 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single intravenous (IV) infusion of OP-101 2 milligram per kilogram (mg/kg) on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: OP-101 4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IV infusion of OP-101 4 mg/kg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: OP-101 8 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IV infusion of OP-101 8 mg/kg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single IV infusion of matching placebo on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OP-101</intervention_name>
    <description>OP-101 infusion will be administered intravenously.</description>
    <arm_group_label>Cohort A: OP-101 2 mg/kg</arm_group_label>
    <arm_group_label>Cohort B: OP-101 4 mg/kg</arm_group_label>
    <arm_group_label>Cohort C: OP-101 8 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo infusion will be administered intravenously.</description>
    <arm_group_label>Cohort D: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Body mass index (BMI) less than or equal to (&lt;=) 35 kilogram per meter square (kg/m^2)

          -  Positive laboratory test for severe acute respiratory syndrome coronavirus 2
             (SARS-CoV-2) or respiratory infection with recent exposure to a person with
             laboratory-proven SARS-CoV-2

          -  Hypoxemia defined by saturation of peripheral oxygen (SpO2) of less than (&lt;) 95
             percent (%) on room air or Acute respiratory distress syndrome (ARDS)

          -  Occurrence of at least two of the following criteria: fever greater than (&gt;) 38.0
             degree celsius, tachycardia &gt;90 beats/minute, tachypnea &gt;20 breaths/minute,
             leucocytosis &gt;12*109 per liter (/L) or leucopoenia &lt;4 *109/L

          -  Participants must have an estimated glomerular filtration rate of greater than or
             equal to (&gt;=) 45 milliliter per minute per 1.73 meter square (mL/min/1.73 m^2) at
             screening

        Key Exclusion Criteria:

          -  Not expected to survive for more than 24 hours

          -  Severe chronic obstructive pulmonary disease requiring long-term home oxygen therapy
             or mechanical ventilation (noninvasive ventilation or via tracheotomy) except for
             continuous positive airway pressure or bi-level positive airway pressure used solely
             for sleep-disordered breathing

          -  Acute left ventricular failure or myocardial infarction

          -  Currently receiving extracorporeal membrane oxygenation (ECMO) therapy

          -  Receiving renal dialysis therapy for chronic renal failure

          -  Concurrent treatment with immune modulatory study drugs (e.g., anti-IL6 antibodies,
             Janus kinase (JAK) kinase inhibitors) or other agents with actual or possible direct
             acting antiviral activity against SARS-CoV-2 within 30 days or 5 half-lives, whichever
             is longer, prior to dosing with OP-101; except for those that have received FDA
             emergency-use authorization and have become standard of care (SOC). Concurrent
             treatment with corticosteroids is permitted if participant has documented continued
             hypoxemia (SpO2 of &lt;95% on room air) and hyper-inflammation (CRP&gt;=10mg/L) at
             screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeffrey L. Cleland, Executive Chair, Co-founder</last_name>
    <phone>+1 650 241 1697</phone>
    <email>cleland@orpheris.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>H. Bryant Nguyen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sunil Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ishan Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nauder Faraday, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aaron Gusdon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-COV-2</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>Cytokine storm</keyword>
  <keyword>Acute respiratory distress syndrome</keyword>
  <keyword>Inflammation</keyword>
  <keyword>IL-6</keyword>
  <keyword>Treatment</keyword>
  <keyword>OP-101</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

